TrialNature medicine2023

Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study.

Beverley M Shields et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.